Join to access to all OVN content. Join for Free

Results for 'review'

...
Partner Avatar Michael Pietrack
Leadership Lab: Take a Cue From Athletes by Working With an Executive Coach

Feb 19th • 6 mins read

...
Partner Avatar Michael Pietrack
Leadership Lab: 4 Ways Biopharma Leaders Can Prepare for Media Interviews

Aug 20th • 6 mins read

...
Partner Avatar Michael Pietrack
Practical Advice for When You're Downsized. What Activities will Pay-off after a Lay-off?

Sep 15th • 5 mins read

...
Partner Avatar Michael Pietrack
The Four Employment Agreement Questions Every Pharma Executive Must Ask

Dec 18th • 6 mins read

...
Partner Avatar Tom Caravela
Where Did My Interview Go Wrong?

Apr 24th • 1 min read

...
Partner Avatar Tom Caravela
12 Interview Techniques to Help Land Your Next Job

May 12th • 1 min read

...
Partner Avatar Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons

May 17th • 2 mins read

...
Partner Avatar Tom Caravela
10 Ways to Make an Impact on a Phone Interview

Apr 9th • 1 min read

...
Partner Avatar Tom Caravela
Resume Writing and Editing Tips for Pharma Professionals

Aug 8th • 1 min read

...
Partner Avatar Bridget Rasmusson
6 Tips to Ace Your Next MSL Interview!

Sep 28th • 1 min read

...
Partner Avatar Tom Caravela
MSL People Skills: Top 10 Tips for Better Engagement

Apr 20th • 8 mins read

...
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

May 6th • 18 mins read

...
OVN Avatar Adela Rodriguez, Francis Esposito, Helena Oliveres, Ferran Torres and Joan Maurel
Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

Feb 11th • 3 mins read

...
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Mar 12th • 7 mins read

...
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Feb 11th • 4 mins read

...
OVN Avatar Jorge J. García, Luis E. Raez, Daniel Rosas
A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation

Aug 3rd • 10 mins read

...
OVN Avatar Shani Paluch-Shimon, Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni, Martine J. Piccart, Nicola Jane Latino, Fatima Cardoso
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

Sep 6th • 20 mins read

...
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Aug 16th • 8 mins read

...
OVN Avatar Consolación Molto MD, Thomas J. Hwang AB, Maria Borrell MD, Marta Andres MD, Ignasi Gich MD, PhD, Agustí Barnadas MD, PhD, Eitan Amir MD, PhD, Aaron S. Kesselheim MD, JD, MPH, Ariadna Tibau MD, PhD
Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

Jul 22nd • 12 mins read

...
OVN Avatar Cornelius F Waller & Adriano Friganovi´c
Biosimilars in oncology: key role of nurses in patient education

Jun 15th • 10 mins read

Related Topics

Loading...